<?xml version="1.0" encoding="UTF-8"?>
<p id="p0185">Due to the current public health emergency due to COVID-19, the U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) of the experimental drug remdesivir [
 <xref rid="bib25" ref-type="bibr">25</xref>,
 <xref rid="bib26" ref-type="bibr">26</xref>]. However, the efficacy and safety of remdesivir remain controversial. The Japanese Ministry of Health, Labour and Welfare has also approved remdesivir as a treatment for COVID-19. In addition, the combination of α-interferon and the anti-human immunodeficiency virus (HIV) drug lopinavir/ritonavir (Kaletra®) has been used to treat COVID-19, but the evidence regarding its effectiveness remains still limited, and the drug might have toxic side effects [
 <xref rid="bib26" ref-type="bibr">[26]</xref>, 
 <xref rid="bib27" ref-type="bibr">[27]</xref>, 
 <xref rid="bib28" ref-type="bibr">[28]</xref>]. Therefore, the development of highly specific and effective anti-coronavirus drugs against key viral targets, particularly SARS-CoV-2, is urgently needed and would also be of great significance for preventing and treating the recurrence of coronavirus epidemics in the future.
</p>
